KR102435956B1 - 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법 - Google Patents

글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법 Download PDF

Info

Publication number
KR102435956B1
KR102435956B1 KR1020177012950A KR20177012950A KR102435956B1 KR 102435956 B1 KR102435956 B1 KR 102435956B1 KR 1020177012950 A KR1020177012950 A KR 1020177012950A KR 20177012950 A KR20177012950 A KR 20177012950A KR 102435956 B1 KR102435956 B1 KR 102435956B1
Authority
KR
South Korea
Prior art keywords
acid
compound
receptor
liver
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177012950A
Other languages
English (en)
Korean (ko)
Other versions
KR20170066646A (ko
Inventor
조셉 케이. 빌란오프
헤이즐 헌트
오노 씨. 마이어
호세 반 덴 휴벨
Original Assignee
코어셉트 쎄라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코어셉트 쎄라퓨틱스 인코포레이티드 filed Critical 코어셉트 쎄라퓨틱스 인코포레이티드
Publication of KR20170066646A publication Critical patent/KR20170066646A/ko
Application granted granted Critical
Publication of KR102435956B1 publication Critical patent/KR102435956B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177012950A 2014-10-15 2015-10-14 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법 Active KR102435956B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
KR20170066646A KR20170066646A (ko) 2017-06-14
KR102435956B1 true KR102435956B1 (ko) 2022-08-23

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012950A Active KR102435956B1 (ko) 2014-10-15 2015-10-14 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (3) EP4792880A2 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN107106562B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (2) DK4353310T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (2) FI4353310T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (2) PT4353310T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
CA3102099C (en) * 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
KR102911885B1 (ko) 2020-05-06 2026-01-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체
AU2021266739B2 (en) * 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
JP7853982B2 (ja) * 2020-12-21 2026-04-30 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
AU2022271209B2 (en) * 2021-05-05 2026-07-02 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation
EP4732836A1 (en) 2024-10-22 2026-04-29 Consejo Superior De Investigaciones Científicas Ag5 compound for use in the treatment of in fatty liver diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
EP1883624B1 (en) 2005-05-18 2010-04-07 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
AU2006292293B2 (en) * 2005-09-19 2012-09-13 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20100144764A1 (en) * 2007-04-13 2010-06-10 Schering Corporation Pyrimidinedione derivatives and methods of use thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
CN103596431B (zh) * 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ulrike Lemke, et al., The glucocorticoid receptor controls hepatic dyslipidemia through Hes1, Cell Metabolism, 2008, 8, 212-223. (2008.09.08.)*
공개특허공보 제10-2014-0041463호 (2014.04.04.)*

Also Published As

Publication number Publication date
CN107106562B (zh) 2020-08-18
SG11201703024VA (en) 2017-05-30
EP3206692B1 (en) 2024-04-03
PT4353310T (pt) 2026-07-17
EP4353310A3 (en) 2024-06-19
US20210085682A1 (en) 2021-03-25
IL251729B (en) 2020-03-31
US20230218621A1 (en) 2023-07-13
CN107106562A (zh) 2017-08-29
JP6761410B2 (ja) 2020-09-23
MX2017004943A (es) 2017-07-19
EP4792880A2 (en) 2026-08-19
DK4353310T3 (da) 2026-08-03
FI4353310T3 (fi) 2026-08-04
BR112017007860B1 (pt) 2023-03-07
US20190151318A1 (en) 2019-05-23
NZ731060A (en) 2023-07-28
AU2015333645A1 (en) 2017-05-04
UA123537C2 (uk) 2021-04-21
US12226417B2 (en) 2025-02-18
FI3206692T3 (fi) 2024-05-06
RU2017114596A (ru) 2018-11-15
ZA201702813B (en) 2019-05-29
RU2017114596A3 (enExample) 2019-05-08
US20160106749A1 (en) 2016-04-21
CN111557942B (zh) 2023-10-03
WO2016061195A1 (en) 2016-04-21
AU2015333645B2 (en) 2020-01-30
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
BR112017007860A2 (pt) 2018-01-16
CA2964625C (en) 2023-03-07
IL251729A0 (en) 2017-06-29
EP3206692A4 (en) 2018-05-30
JP2017531013A (ja) 2017-10-19
US10238659B2 (en) 2019-03-26
CN111557942A (zh) 2020-08-21
EP4353310B1 (en) 2026-07-01
PH12017500710A1 (en) 2017-10-09
KR20170066646A (ko) 2017-06-14
RU2718921C2 (ru) 2020-04-15
DK3206692T3 (da) 2024-04-29
EP3206692A1 (en) 2017-08-23
CA2964625A1 (en) 2016-04-21
ES2978871T3 (es) 2024-09-23
PH12017500710B1 (en) 2024-01-17
US11590135B2 (en) 2023-02-28
EP4353310A2 (en) 2024-04-17
PL3206692T3 (pl) 2024-07-22
PT3206692T (pt) 2024-04-30

Similar Documents

Publication Publication Date Title
US12226417B2 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
US12263169B2 (en) Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP3509584A1 (en) Glucocorticoid receptor modulators to treat pancreatic cancer
KR20070115879A (ko) 의학 장애의 치료용 ｃｘｃｒ4 길항제
KR20180116372A (ko) 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
US10245255B2 (en) Compositions and methods for the treatment of obesity and related disorders
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
CN104644639A (zh) 用于调控激酶级联的药物组合物及其使用方法
EP4103180A1 (en) Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator
HK40102771A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
JP2025517441A (ja) クッシング症候群及び肝障害を治療する方法、並びに患者に投与される他の薬物の肝毒性を低減する方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4